Extracranial skeletal metastasis in anaplastic oligodendroglioma: Case report and review of the literature

Journal of International Medical Research

Volumn 39, Issue 3, 2011, Pages 960-967

  Wu, Y ^a   Liu, B ^a   Qu, L ^b   Tao, H ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Binjiang Hospital of Hangzhou   (China)

Author keywords

Anaplastic oligodendroglioma; Chemotherapy; Genetic analysis; Metastasis

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; MEDRONATE TECHNETIUM TC 99M; PROTEIN S 100; TEMOZOLOMIDE;

ADULT; ANAMNESIS; ANAPLASTIC OLIGODENDROGLIOMA; BONE BIOPSY; BONE METASTASIS; BONE RADIOGRAPHY; BONE SCINTISCANNING; BRAIN CORTEX; BRAIN TUMOR; CANCER GRADING; CANCER RADIOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CRANIOTOMY; DIZZINESS; EPILEPSY; FEMUR; HEADACHE; HEMIPARESIS; HIP PAIN; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; OSTEOSCLEROSIS; PARIETOTEMPORAL CORTEX; REVIEW; TUMOR LOCALIZATION;

EID: 80052252196     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001103900331     Document Type: Review

References (44)

1. Louis DN, Ohgaki H, Wiestler OD, et al: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97-109.
2. Shaw EG, Scheithauer BW, O'Fallon JR, et al: Oligodendrogliomas: the Mayo Clinic experience. J Neurosurg 1992; 76: 428-434.
3. Medical Research Council: Aids to the Examination of the Peripheral Nervous System. Memorandum No. 45. London: HMSO, 1976.
4. Engelhard HH, Stelea A, Mundt A: Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis. Surg Neurol 2003; 60: 443-456.
5. Celli P, Nofrone I, Palma L, et al: Cerebral oligodendroglioma: prognostic factors and life history. Neurosurgery 1994; 35: 1018-1034.
6. Lee CC, Jiang JS, Chen ET, et al: Cytologic diagnosis of a metastatic oligodendroglioma in a pleural effusion. A case report. Acta Cytol 2006; 50: 542-544.
7. Merrell R, Nabors LB, Perry A, et al: 1p/19q chromosome deletions in metastatic oligodendroglioma. J Neurooncol 2006; 80: 203-207.
8. Noshita N, Mashiyama S, Fukawa O, et al: Extracranial metastasis of anaplastic oligodendroglioma with 1p19q loss of heterozygosity-case report. Neurol Med Chir (Tokyo) 2010; 50: 161-164.
9. Jellinger K, Minauf M, Salzer-Kuntschik M: Oligodendroglioma with extraneural metastases. J Neurol Neurosurg Psychiatry 1969; 32: 249-253.
10. Schuster H, Jellinger K, Gund A, et al: Extracranial metastases of anaplastic cerebral gliomas. Acta Neurochir (Wien) 1976; 35: 247-259.
11. Volavsek M, Lamovec J, Popović M: Extraneural metastases of anaplastic oligodendroglial tumors. Pathol Res Pract 2009; 205: 502-507.
12. Giordana MT, Ghimenti C, Leonardo E, et al: Molecular genetic study of a metastatic oligodendroglioma. J Neurooncol 2004; 66: 265-271.
13. Pansera F, Pansera E: An explanation for the rarity of extraaxial metastases in brain tumors. Med Hypotheses 1992; 39: 88-89.
14. Gamis AS, Egelhoff J, Roloson G, et al: Diffuse bony metastases at presentation in a child with glioblastoma multiforme. A case report. Cancer 1990; 66: 180-184.
15. Liwnicz BH, Rubinstein LJ: The pathways of extraneural spread in metastasizing gliomas: a report of three cases and critical review of the literature. Hum Pathol 1979; 10: 453-467.
16. Fortin D, Macdonald DR, Stitt L, et al: PCV for oligodendroglial tumors: in search of prognostic factors for response and survival. Can J Neurol Sci 2001; 28: 215-223.
17. Frank S, Kuhn SA, Brodhun M, et al: Metastatic glioblastoma cells use common pathways via blood and lymphatic vessels. Neurol Neurochir Pol 2009; 43: 183-190.
18. Al-Ali F, Hendon AJ, Liepman MK, et al: Oligodendroglioma metastatic to bone marrow. AJNR Am J Neuroradiol 2005; 26: 2410-2414.
19. Han SR, Yoon SW, Yee GT, et al: Extraneural metastases of anaplastic oligodendroglioma. J Clin Neurosci 2008; 15: 946-949.
20. Zustovich F, Della Puppa A, Scienza R, et al: Metastatic oligodendrogliomas: a review of the literature and case report. Acta Neurochir (Wien) 2008; 150: 699-702.
21. Wang X, Hisha H, Taketani S, et al: Neural cell adhesion molecule contributes to hemopoiesissupporting capacity of stromal cell lines. Stem Cells 2005; 23: 1389-1399.
22. Cairncross JG, Ueki K, Zlatescu MC, et al: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998; 90: 1473-1479.
23. van den Bent MJ, Looijenga LH, Langenberg K, et al: Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 2003; 97: 1276-1284.
24. Davis FG, McCarthy BJ, Freels S, et al: The conditional probability of survival of patients with primary malignant brain tumors: surveillance, epidemiology, and end results (SEER) data. Cancer 1999; 85: 485-491.
25. Scott CB, Scarantino C, Urtasun R, et al: Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys 1998; 40: 51-55.
26. Jenkins RB, Blair H, Ballman KV, et al: A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006; 66: 9852-9861.
27. Fallon KB, Palmer CA, Roth KA, et al: Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. J Neuropathol Exp Neurol 2004; 63: 314-322.
28. Campbell BA, Horsman DE, Maguire J, et al: Chromosomal alterations in oligodendroglial tumours over multiple surgeries: is tumour progression associated with change in 1p/19q status? J Neurooncol 2008; 89: 37-45.
29. Broderick DK, Di C, Parrett TJ, et al: Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res 2004; 64: 5048 -5050.
30. Sasaki H, Zlatescu MC, Betensky RA, et al: PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol 2001; 159: 359-367.
31. Ino Y, Betensky RA, Zlatescu MC, et al: Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 2001; 7: 839-845.
32. van den Bent MJ, Taphoorn MJ, Brandes AA, et al: Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 2003; 21: 2525-2528.
33. Hoang-Xuan K, Capelle L, Kujas M, et al: Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004; 22: 3133-3138.
34. Levin N, Lavon I, Zelikovitsh B, et al: Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer 2006; 106: 1759-1765.
35. Kim JT, Kim JS, Ko KW, et al: Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas. Oncol Rep 2006; 16: 33-39.
36. Kurzen H, Schmitt S, Näher H, et al: Inhibition of angiogenesis by non-toxic doses of temozolomide. Anticancer Drugs 2003; 14: 515-522.
37. Lage H, Dietel M: Involvement of the DNA mismatch repair system in antineoplastic drug resistance. J Cancer Res Clin Oncol 1999; 125: 156-165.
38. Schiff D, Brown PD, Giannini C: Outcome in adult low-grade glioma: the impact of prognostic factors and treatment. Neurology 2007; 69: 1366-1373.
39. Ziegler DS, Kung AL, Kieran MW: Antiapoptosis mechanisms in malignant gliomas. J Clin Oncol 2008; 26: 493-500.
40. Villano JL, Seery TE, Bressler LR: Temozolomide in malignant gliomas: current use and future targets. Cancer Chemother Pharmacol 2009; 64: 647-655.
41. Kesari S, Schiff D, Drappatz J, et al: Phase II study of protracted daily temozolomide for lowgrade gliomas in adults. Clin Cancer Res 2009; 15: 330-337.
42. Taliansky-Aronov A, Bokstein F, Lavon I, et al: Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial. J Neurooncol 2006; 79: 153-157.
43. van den Bent MJ: Diagnosis and management of oligodendroglioma. Semin Oncol 2004; 31: 645-652.
44. Ducray F, El Hallani S, Idbaih A: Diagnostic and prognostic markers in gliomas. Curr Opin Oncol 2009; 21: 537-542.